EFSD, JDRF and Novo Nordisk renew partnership for type 1 diabetes research in Europe

EFSD, JDRF and Novo Nordisk renew partnership for type 1 diabetes research in Europe

1.8 million euros to further boost European diabetes research

Media Contact:

European Foundation for the Study of Diabetes
Dr Viktor Jörgens

Tel.: +49.211.758.4690
E-mail: [email protected]

Juvenile Diabetes Research Foundation
Joana Casas

Tel.: 212.479.7560
E-mail: [email protected]

Novo Nordisk A/S
Katrine Sperling

Tel.: +45.4442.6718
[email protected]

Stockholm, Sweden, Sept. 22, 2010 --- The European Foundation for the Study of Diabetes (EFSD), the Juvenile Diabetes Research Foundation (JDRF) and Novo Nordisk A/S announced today the renewal of their partnership to support type 1 diabetes research in Europe. The announcement was made at the European Association for the Study of Diabetes (EASD) annual meeting in Stockholm, Sweden, today.

Established in 2004, this ongoing partnership for research into type 1 diabetes encourages new projects aimed at advancing current knowledge in this area. Together, the three partners are committing a further 1.8 million euros which will fund a wide range of European-based diabetes research over the next three years.

Prof. Ulf Smith, President of EASD and EFSD, stressed the importance of increasing funding for diabetes research in Europe: "EFSD is proud to renew our cooperation with JDRF and Novo Nordisk. I hope this partnership will inspire both governments and industry to increase their contributions to research into diabetes."

Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk said: 'More research is needed to understand the pathogenesis and improve therapy of people with type 1 diabetes. We hope that this partnership will generate new important knowledge and support scientists in working towards our common goal of defeating diabetes.'

The EFSD/JDRF/Novo Nordisk European Programme in Type 1 Diabetes Research will accept applications within any area of basic or clinical diabetes research focusing on type 1 diabetes and its complications.

According to Dr. Richard Insel, Chief Scientific Officer of JDRF, "JDRF is excited about renewing our partnership with EFSD and Novo Nordisk to support promising type 1 diabetes research in Europe. Our shared goal is to promote novel discoveries and their translation into therapeutics."


The European Foundation for the Study of Diabetes (EFSD) was created by the European Association for the Study of Diabetes (EASD) to provide multiple funding initiatives in all areas of diabetes research. The aims of EFSD are to encourage and support research in the field of diabetes, to rapidly diffuse acquired knowledge and to facilitate its application.

JDRF is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder and advocate of type 1 diabetes research.  The mission of JDRF is to find a cure for diabetes and its complications through the support of research.  Type 1 diabetes is a disease which strikes children and adults suddenly and requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it prevent its devastating complications which may include kidney failure, blindness, heart disease, stroke, and amputation.  Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.4 billion to diabetes research, including more than $100 million last year.

Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

About JDRF

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal.

Since its founding in 1970, JDRF has awarded more than $1.6 billion to diabetes research. Past JDRF efforts have helped to significantly advance the care of people with this disease, and have expanded the critical scientific understanding of T1D. JDRF will not rest until T1D is fully conquered. 

Lets turn type one into type none